Update on community-acquired pneumonia

Recent years have witnessed the emergence of new pathogens linked to community-acquired pneumonia (CAP) along with new antibiotics designed to combat them. In this article, Dr Mandell presents an expert's view on these developments in the context of treatment guidelines for CAP. He also explores monotherapy versus combination therapy, the efficacy of rapid initiation of treatment, and short-course therapy as a hedge against antimicrobial resistance.